Condition: Diffuse Large B-Cell Lymphoma · Chronic Lymphocytic Leukemia · Follicular Lymphoma · Sponsor: AbbVie
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), R/R follicular lymphoma (FL), or R/R CLL. Adverse events will be assessed. ABBV-319 is an investigational drug being developed for the treatment of R/R DLBCL, R/R FL, or R/R CLL. This study will include a dose escalation phase to determine the doses of ABBV-319 that will be used in the next phase and a dose expansion phase to determine the change in disease activity in participants with R/R DLBCL, R/R FL, and R/R CLL. Approximately 154 adult participants with R/R B cell lymphomas including R/R DLBCL, R/R FL, and R/R CLL will be enrolled in the study in sites world wide. In the Dose Escalation phase of the study participants will receive escalating intravenously infused doses of ABBV-319 in 21-day cycles, until the Phase 2 dose is determined. In the dose expansion phase of the study participants receive intravenously infused ABBV-319 in 21-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend reg…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| University of Arizona Cancer Center - Tucson /ID# 247752 | Tucson, Arizona, United States | Recruiting |
| Sylvester Comprehensive Cancer Center - University of Miami /ID# 247232 | Miami, Florida, United States | Completed |
| Allina Health System /ID# 251782 | Minneapolis, Minnesota, United States | Recruiting |
| University of Nebraska Medical Center /ID# 246715 | Omaha, Nebraska, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center-Koch Center /ID# 249246 | New York, New York, United States | Recruiting |
| Novant Health Presbyterian Medical Center /ID# 246719 | Charlotte, North Carolina, United States | Recruiting |
| Baylor Sammons Cancer Center /ID# 247715 | Dallas, Texas, United States | Recruiting |
| University of Texas Health San Antonio MD Anderson Cancer Center /ID# 256234 | San Antonio, Texas, United States | Recruiting |
| Concord Repatriation General Hospital /ID# 249240 | Concord, New South Wales, Australia | Recruiting |
| St Vincent's Hospital Melbourne /ID# 247624 | Fitzroy Melbourne, Victoria, Australia | Recruiting |
| One Clinical Research Pty Ltd /ID# 248392 | Nedlands, Western Australia, Australia | Recruiting |
| Cross Cancer Institute /ID# 246717 | Edmonton, Alberta, Canada | Completed |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05512390